Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Bodine P.S. Belderbos; Ronald de Wit; Esther Oomen-de Hoop; Annemieke Nieuweboer; Paul Hamberg; Robbert J. van Alphen; André Bergman; Nelly van der Meer; Sander Bins; Ron H.J. Mathijssen; Robert J. van Soest

doi:10.18632/oncotarget.22474

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Bodine P.S. Belderbos _, Ronald de Wit, Esther Oomen-de Hoop, Annemieke Nieuweboer, Paul Hamberg, Robbert J. van Alphen, André Bergman, Nelly van der Meer, Sander Bins, Ron H.J. Mathijssen and Robert J. van Soest

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:106468-106474. https://doi.org/10.18632/oncotarget.22474

Metrics: PDF 1320 views | HTML 1948 views | ?

Abstract

Bodine P.S. Belderbos1, Ronald de Wit1, Esther Oomen-de Hoop1, Annemieke Nieuweboer1, Paul Hamberg2, Robbert J. van Alphen3, André Bergman4, Nelly van der Meer1, Sander Bins1, Ron H.J. Mathijssen1 and Robert J. van Soest5

1Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, 3015 CE Rotterdam, The Netherlands

2Department of Internal Medicine, Franciscus Gasthuis and Vlietland, 3045 PM Rotterdam, The Netherlands

3Department of Internal Medicine, Elisabeth Tweesteden Ziekenhuis, 5042 AD Tilburg, The Netherlands

4Department of Medical Oncology, Netherlands Cancer Institute–Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands

5Department of Urology, Erasmus University Medical Center and Cancer Institute, 3015 CE Rotterdam, The Netherlands

Correspondence to:

Bodine P.S. Belderbos, email: [email protected]

Keywords: prognostic factors; cabazitaxel; mCRPC; overall survival; PSA response

Received: August 08, 2017 Accepted: October 27, 2017 Published: November 16, 2017

ABSTRACT

Background: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel.

Results: 224 mCRPC patients were included in the current analysis. In multivariable analysis, WHO performance status, baseline hemoglobin, alkaline phosphatase and albumin were all significantly associated with OS. Hemoglobin and alkaline phosphatase were significantly associated with PSA response.

Conclusions: This study identified prognostic factors for OS and PSA response of men with mCRPC treated with cabazitaxel. In an increasingly complicated treatment landscape with several treatment options available our findings might serve to estimate the chance of survival of men qualifying for treatment with second-line chemotherapy in daily practice. Furthermore, these data can be used to risk-stratify patients in clinical trials.

Methods: We performed a post-hoc analysis of a randomized phase II trial of mCRPC patients treated with cabazitaxel. Cox and logistic regression models were used to investigate the influence of clinical and biochemical variables on OS and PSA response. Nomograms were developed to estimate the chance of PSA response and OS.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22474

Publication Alerts

Research Papers:

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Abstract